NASDAQ: HOWLWerewolf Therapeutics Inc Stock Ownership - Who owns Werewolf Therapeutics?
Insider buying vs selling
Have Werewolf Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Ra Capital Management LP | Director | 2025-05-14 | 162,539 | $0.98 | $159.29kBuy |
| Ra Capital Management LP | Director | 2025-05-13 | 52,974 | $0.98 | $51.91kBuy |
| Ra Capital Management LP | Director | 2025-05-12 | 320,913 | $0.86 | $275.99kBuy |
| Ansbert Gadicke | 10% Owner | 2025-03-27 | 4,386 | $1.05 | $4.61kSell |
| Luke Evnin | Director | 2025-03-27 | 28,113 | $0.09 | $2.53kBuy |
| Mpm Bioventures 2014 LP | 10% Owner | 2025-03-27 | 1,963 | $1.05 | $2.06kSell |
| Mpm Bioventures 2014 LP | 10% Owner | 2025-03-27 | 22,758 | $0.09 | $2.05kBuy |
| Luke Evnin | Director | 2025-03-27 | 2,425 | $1.05 | $2.55kSell |
| Ansbert Gadicke | 10% Owner | 2025-03-27 | 50,873 | $0.09 | $4.58kBuy |
HOWL insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when HOWL insiders and whales buy or sell their stock.
HOWL Shareholders
What type of owners hold Werewolf Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Ansbert Gadicke | 14.97% | 6,718,670 | $8.73M | Insider |
| Ra Capital Management LP | 13.69% | 6,144,881 | $7.99M | Institution |
| Mpm Asset Management LLC | 9.60% | 4,309,860 | $5.60M | Institution |
| Luke Evnin | 9.60% | 4,309,860 | $5.60M | Insider |
| Mpm Bioventures 2014 LP | 7.15% | 3,208,793 | $4.17M | Insider |
| James E. Flynn | 5.69% | 2,552,787 | $3.32M | Insider |
| Pfm Health Sciences LP | 5.59% | 2,506,520 | $3.26M | Institution |
| Mpm Bioimpact LLC | 5.37% | 2,408,810 | $3.13M | Institution |
| Bank Of America Corp | 4.69% | 2,103,142 | $2.73M | Institution |
| Sakae Asanuma | 4.61% | 2,068,909 | $2.69M | Insider |
HOWL vs Biotech Stocks
Werewolf Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.